- Home
- CGAU vs ZYME Comparison
CGAU vs ZYME Comparison
Compare CGAU & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CGAU | ZYME |
|---|---|---|
| Founded | 2002 | 2003 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 1.8B |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CGAU | ZYME |
|---|---|---|
| Price | $17.64 | $22.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | $16.00 | ★ $38.90 |
| AVG Volume (30 Days) | ★ 1.4M | 630.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.09% | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $105,965,000.00 |
| Revenue This Year | $23.72 | $162.82 |
| Revenue Next Year | $13.78 | N/A |
| P/E Ratio | $11.74 | ★ N/A |
| Revenue Growth | N/A | ★ 38.87 |
| 52 Week Low | $5.41 | $9.03 |
| 52 Week High | $21.17 | $28.49 |
Technical Indicators
Market Signals| Indicator | CGAU | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 42.99 | 43.81 |
| Support Level | $17.51 | $22.23 |
| Resistance Level | $20.49 | $23.66 |
| Average True Range (ATR) | 0.94 | 1.42 |
| MACD | -0.28 | -0.05 |
| Stochastic Oscillator | 0.98 | 9.06 |
Price Performance
Historical ComparisonAbout CGAU Centerra Gold Inc.
Centerra Gold Inc is principally focused on operating, developing, exploring and acquiring gold and copper properties in North America, Turkey, and other markets world-wide. The company reportable operating segments are Oksut; Mount Milligan; and Molybdenum. It derives maximum revenue from Mount Milligan segment. Geographically, it operates in Turkey, United States, and Canada.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.